Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 17/20 | 1.00 |
| ▸ | CYP1A1 | P04798 | 17/20 | 1.00 |
| ▸ | CYP1B1 | Q16678 | 17/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | CYP2E1 | P05181 | 1/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2A6 | P11509 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP4B1 | P13584 | 1/20 | 1.00 |
| ▸ | CYP2B6 | P20813 | 1/20 | 1.00 |
| ▸ | CYP3A5 | P20815 | 1/20 | 1.00 |
| ▸ | CYP2A7 | P20853 | 1/20 | 1.00 |
| ▸ | CYP3A7 | P24462 | 1/20 | 1.00 |
| ▸ | CYP2F1 | P24903 | 1/20 | 1.00 |
| ▸ | CYP2C18 | P33260 | 1/20 | 1.00 |
| ▸ | CYP2J2 | P51589 | 1/20 | 1.00 |
| ▸ | CYP4F2 | P78329 | 1/20 | 1.00 |
| ▸ | CYP4F8 | P98187 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30090378 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP1A1CYP1B1CYP3A4CYP2C19 | |
| SCHEMBL17675325 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP1A1CYP1B1CYP3A4CYP2C19 | |
| SCHEMBL4366766 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP1A1CYP1B1CYP3A4CYP2C19 | |
| SCHEMBL25706432 | 0.89 | CYP1A2 (1.00) | CYP1A2CYP1A1CYP1B1CYP3A4CYP2C19 | |
| SCHEMBL5495431 | 0.87 | CYP1A2 (1.00) | CYP1A2CYP1A1CYP1B1CYP3A4CYP2C19 | |
| SCHEMBL5495428 | 0.87 | CYP1A2 (1.00) | CYP1A2CYP1A1CYP1B1CYP3A4CYP2C19 | |
| Resveratrol SCHEMBL9273945 | 0.87 | CYP1A1 (0.76) | CYP1A2CYP1A1CYP1B1CYP3A4CYP2C19 | |
| SCHEMBL15288712 | 0.86 | CYP1A2 (1.00) | CYP1A2CYP1A1CYP1B1CYP3A4CYP2C19 | |
| SCHEMBL15288715 | 0.86 | CYP1A2 (1.00) | CYP1A2CYP1A1CYP1B1CYP3A4CYP2C19 | |
| SCHEMBL15781554 | 0.85 | CYP1A2 (0.73) | CYP1A2CYP1A1CYP1B1CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240269066-A1 | USE OF CYP450 INHIBITOR IN INHIBITING OR KILLING MITES AND TREATING XEROPHTHALMIA | PRECVISION BIOTECHNOLOGIES LTD. (CN) | 2024-08-15 | — | — | US | claimed |
| EP-4353264-A1 | USE OF CYP450 INHIBITOR IN INHIBITING OR KILLING MITES AND TREATING DRY EYE SYNDROME | Precvision Biotechnologies Ltd. (CN) | 2024-04-17 | — | — | EP | claimed |
| CN-117561081-A | Application of CYP450 inhibitor in inhibiting or killing mites and treating xerophthalmia | 广州珍实视界生物医药科技有限公司 | 2024-02-13 | — | — | CN | claimed |
| US-20230033047-A1 | Estrogen Metabolite Levels And Cancer Driver Gene Mutations In Lung Cancer Risk Stratification And Treatment | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER | 2023-02-02 | — | — | US | claimed |
| WO-2022257986-A1 | USE OF CYP450 INHIBITOR IN INHIBITING OR KILLING MITES AND TREATING DRY EYE SYNDROME | 广州岐微生物医药科技有限公司 | 2022-12-15 | — | — | WO | claimed |
| EP-4087660-A1 | ESTROGEN METABOLITE LEVELS AND CANCER DRIVER GENE MUTATIONS IN LUNG CANCER RISK STRATIFICATION AND TREATMENT | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center (US) | 2022-11-16 | — | — | EP | claimed |
| WO-2021142408-A1 | ESTROGEN METABOLITE LEVELS AND CANCER DRIVER GENE MUTATIONS IN LUNG CANCER RISK STRATIFICATION AND TREATMENT | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2021-07-15 | — | — | WO | claimed |
| US-20190209618-A1 | METHODS AND COMPOSITIONS FOR EXPANSION OF HEMATOPOIETIC STEM AND/OR PROGENITOR CELLS EMPLOYING A CYTOCHROME P450 1B1 (CYP1B1) INHIBITOR OR A MUSASHI-2 (MSI2) ACTIVATOR | MCMASTER UNIVERSITY (CA) | 2019-07-11 | — | — | US | claimed |
| WO-2017185179-A1 | METHODS AND COMPOSITIONS FOR EXPANSION OF HEMATOPOIETIC STEM AND/OR PROGENITOR CELLS EMPLOYING A CYTOCHROME P450 1B1 (CYP1B1) INHIBITOR OR A MUSASHI-2 (MSI2) ACTIVATOR | MCMASTER UNIVERSITY (CA) | 2017-11-02 | — | — | WO | claimed |
| WO-2009001046-A2 | [11C]METHOXY-RADIOLABELLED 2,3',4,5'-TETRAMETHYLSTILBENE (TMS) AND ITS PREPARATION AND USE | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2008-12-31 | — | — | WO | claimed |
| US-12448437-B2 | Transplant tolerance induction with carbodiimide treated tolerizing vaccine | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2025-10-21 | — | — | US | disclosed |
| WO-2025101983-A1 | NON-STEROIDAL ISONITRILE BINDING COMPOUNDS OF CYTOCHROME P450 SUBTYPES | BRANDEIS UNIVERSITY (US) | 2025-05-15 | — | — | WO | disclosed |
| EP-4417212-A2 | TRANSPLANT TOLERANCE INDUCTION WITH CARBODIIMIDE TREATED TOLERIZING VACCINE | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2024-08-21 | — | — | EP | disclosed |
| EP-3866815-B1 | TRANSPLANT TOLERANCE INDUCTION WITH CARBODIIMIDE TREATED TOLERIZING VACCINE | UNIV MINNESOTA (US) | 2024-05-01 | — | — | EP | disclosed |
| CN-117561081-A | Application of CYP450 inhibitor in inhibiting or killing mites and treating xerophthalmia | 广州珍实视界生物医药科技有限公司 | 2024-02-13 | — | — | CN | disclosed |
| WO-2009001046-A2 | [11C]METHOXY-RADIOLABELLED 2,3',4,5'-TETRAMETHYLSTILBENE (TMS) AND ITS PREPARATION AND USE | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2008-12-31 | — | — | WO | disclosed |
| US-20070276172-A1 | Single step microwave induced process for the preparation of substituted stilbenes and its analogs | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2007-11-29 | — | — | US | disclosed |
| WO-2007110883-A1 | A SINGLE STEP MICROWAVE INDUCED PROCESS FOR THE PREPARATION OF SUBSTITUTED STILBENES AND ITS ANALOGS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2007-10-04 | — | — | WO | disclosed |
| US-7253324-B1 | Process for the synthesis of biologically active oxygenated compounds by dealkylation of the corresponding alkylethers | SAMI LABS LIMITED (IN) | 2007-08-07 | — | — | US | disclosed |
| WO-2003018013-A1 | STILBENE DERIVATIVE HAVING CYTOCHROME P450 1B1 INHIBITORY ACTIVITY, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PREPARING THE SAME, AND COMPOSITION INCLUDING THE SAME | PROMEDITECH, INC. (KR) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276172-A1 | Single step microwave induced process for the preparation of substituted stilbenes and its analogs | HRH3, HPD, TET2 | CYP1A2 2162/4885CYP1A1 1101/4885CYP1B1 1452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.